Literature DB >> 29552726

α2A- and α2C-Adrenoceptors as Potential Targets for Dopamine and Dopamine Receptor Ligands.

Marta Sánchez-Soto1,2,3, Verònica Casadó-Anguera2,3, Hideaki Yano1, Brian Joseph Bender4,5, Ning-Sheng Cai1, Estefanía Moreno2,3, Enric I Canela2,3, Antoni Cortés2,3, Jens Meiler4,5, Vicent Casadó6,7, Sergi Ferré8.   

Abstract

The poor norepinephrine innervation and high density of Gi/o-coupled α2A- and α2C-adrenoceptors in the striatum and the dense striatal dopamine innervation have prompted the possibility that dopamine could be an effective adrenoceptor ligand. Nevertheless, the reported adrenoceptor agonistic properties of dopamine are still inconclusive. In this study, we analyzed the binding of norepinephrine, dopamine, and several compounds reported as selective dopamine D2-like receptor ligands, such as the D3 receptor agonist 7-OH-PIPAT and the D4 receptor agonist RO-105824, to α2-adrenoceptors in cortical and striatal tissue, which express α2A-adrenoceptors and both α2A- and α2C-adrenoceptors, respectively. The affinity of dopamine for α2-adrenoceptors was found to be similar to that for D1-like and D2-like receptors. Moreover, the exogenous dopamine receptor ligands also showed high affinity for α2A- and α2C-adrenoceptors. Their ability to activate Gi/o proteins through α2A- and α2C-adrenoceptors was also analyzed in transfected cells with bioluminescent resonance energy transfer techniques. The relative ligand potencies and efficacies were dependent on the Gi/o protein subtype. Furthermore, dopamine binding to α2-adrenoceptors was functional, inducing changes in dynamic mass redistribution, adenylyl cyclase activity, and ERK1/2 phosphorylation. Binding events were further studied with computer modeling of ligand docking. Docking of dopamine at α2A- and α2C-adrenoceptors was nearly identical to its binding to the crystallized D3 receptor. Therefore, we provide conclusive evidence that α2A- and α2C-adrenoceptors are functional receptors for norepinephrine, dopamine, and other previously assumed selective D2-like receptor ligands, which calls for revisiting previous studies with those ligands.

Entities:  

Keywords:  Adenylyl cyclase; BRET; DMR; Docking; ERK1/2 phosphorylation; α2-Adrenoceptors

Mesh:

Substances:

Year:  2018        PMID: 29552726      PMCID: PMC6143434          DOI: 10.1007/s12035-018-1004-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  55 in total

1.  Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs.

Authors:  M G Eason; H Kurose; B D Holt; J R Raymond; S B Liggett
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

Review 2.  The anatomy of dopamine in monkey and human prefrontal cortex.

Authors:  P S Goldman-Rakic; M S Lidow; J F Smiley; M S Williams
Journal:  J Neural Transm Suppl       Date:  1992

3.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

4.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

Review 5.  Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptor-dimer cooperativity index.

Authors:  Vincent Casadó; Antoni Cortés; Francisco Ciruela; Josefa Mallol; Sergi Ferré; Carmen Lluis; Enric I Canela; Rafael Franco
Journal:  Pharmacol Ther       Date:  2007-06-14       Impact factor: 12.310

6.  Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway.

Authors:  Lily I Jiang; Julie Collins; Richard Davis; Keng-Mean Lin; Dianne DeCamp; Tamara Roach; Robert Hsueh; Robert A Rebres; Elliott M Ross; Ronald Taussig; Iain Fraser; Paul C Sternweis
Journal:  J Biol Chem       Date:  2007-02-05       Impact factor: 5.157

7.  Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain.

Authors:  Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-09-09       Impact factor: 9.236

8.  Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study.

Authors:  A P Nicholas; V Pieribone; T Hökfelt
Journal:  J Comp Neurol       Date:  1993-02-22       Impact factor: 3.215

9.  Identification of a Gs coupling domain in the amino terminus of the third intracellular loop of the alpha 2A-adrenergic receptor. Evidence for distinct structural determinants that confer Gs versus Gi coupling.

Authors:  M G Eason; S B Liggett
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

10.  Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist.

Authors:  Marta Sánchez-Soto; Alessandro Bonifazi; Ning Sheng Cai; Michael P Ellenberger; Amy Hauck Newman; Sergi Ferré; Hideaki Yano
Journal:  Mol Pharmacol       Date:  2016-02-03       Impact factor: 4.436

View more
  9 in total

1.  Serotonin receptors contribute to dopamine depression of lateral inhibition in the nucleus accumbens.

Authors:  Dennis A Burke; Veronica A Alvarez
Journal:  Cell Rep       Date:  2022-05-10       Impact factor: 9.995

2.  The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.

Authors:  Elisabeth Singer; Lilit Hunanyan; Magda M Melkonyan; Jonasz J Weber; Lusine Danielyan; Huu Phuc Nguyen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-12

3.  Noradrenergic Signaling Disengages Feedforward Transmission in the Nucleus Accumbens Shell.

Authors:  Kevin M Manz; Benjamin C Coleman; Carrie A Grueter; Brenda C Shields; Michael R Tadross; Brad A Grueter
Journal:  J Neurosci       Date:  2021-03-18       Impact factor: 6.167

4.  Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors.

Authors:  Despoina Aslanoglou; Suzanne Bertera; Marta Sánchez-Soto; R Benjamin Free; Jeongkyung Lee; Wei Zong; Xiangning Xue; Shristi Shrestha; Marcela Brissova; Ryan W Logan; Claes B Wollheim; Massimo Trucco; Vijay K Yechoor; David R Sibley; Rita Bottino; Zachary Freyberg
Journal:  Transl Psychiatry       Date:  2021-02-16       Impact factor: 6.222

5.  A study of the dopamine transporter using the TRACT assay, a novel in vitro tool for solute carrier drug discovery.

Authors:  Hubert J Sijben; Julie J E van den Berg; Jeremy D Broekhuis; Adriaan P IJzerman; Laura H Heitman
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

6.  The hypothalamus predates the origin of vertebrates.

Authors:  Laurence A Lemaire; Chen Cao; Peter H Yoon; Juanjuan Long; Michael Levine
Journal:  Sci Adv       Date:  2021-04-28       Impact factor: 14.136

7.  Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine.

Authors:  Despoina Aslanoglou; Suzanne Bertera; Laura Friggeri; Marta Sánchez-Soto; Jeongkyung Lee; Xiangning Xue; Ryan W Logan; J Robert Lane; Vijay K Yechoor; Peter J McCormick; Jens Meiler; R Benjamin Free; David R Sibley; Rita Bottino; Zachary Freyberg
Journal:  iScience       Date:  2022-07-19

8.  Striatal Neurons Partially Expressing a Dopaminergic Phenotype: Functional Significance and Regulation.

Authors:  Dmitry Troshev; Alyona Bannikova; Victor Blokhin; Anna Kolacheva; Tatiana Pronina; Michael Ugrumov
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

9.  Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors.

Authors:  Hubert J Sijben; Wieke M van Oostveen; Peter B R Hartog; Laura Stucchi; Andrea Rossignoli; Giovanna Maresca; Lia Scarabottolo; Adriaan P IJzerman; Laura H Heitman
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.